KalVista Pharmaceuticals, Inc.

KalVista Pharmaceuticals, Inc. is a global biopharmaceutical company dedicated to the discovery, development, and delivery of life-changing oral therapies for individuals affected by rare diseases with significant unmet needs. The company applies its expertise in the kallikrein-kinin system (KKS) and oral drug discovery to develop small molecule protease inhibitors. Its global corporate headquarters are located in Framingham, Massachusetts, United States, with additional offices in the UK, Utah, Switzerland, and Japan.

KalVista's key product is EKTERLY (sebetralstat), the first and only oral on-demand treatment approved by the U.S. FDA for acute attacks of hereditary angioedema (HAE) in adult and pediatric patients aged 12 years and older. The company's pipeline also includes preclinical programs for oral Factor XIIa inhibitors, aimed at prophylactic treatment of HAE, as well as potential treatments for other conditions such as thrombosis and inflammation.

In a significant recent development, Chiesi Group announced its intent to acquire KalVista Pharmaceuticals for $27 per share in cash, valuing the company at approximately $1.9 billion. This transaction, unanimously approved by both companies' boards, is expected to close in the third quarter of 2026. EKTERLY, which received FDA approval in July 2025, has also secured regulatory approvals in major markets including the EU, UK, Switzerland, Australia, Singapore, and Japan, generating $49.1 million in net product revenue from its commercial launch through December 31, 2025. KalVista is further expanding its market reach by evaluating an orally disintegrating tablet formulation of sebetralstat in the KONFIDENT-KID pediatric trial for younger HAE patients.